CVS vs. Walgreens in 2026: Pharmacy NNN Credit Is No Longer a Coin Flip
For decades, pharmacy net lease assets traded as a near-equivalent pair. CVS or Walgreens on a long-term NNN lease meant investment-grade credit, predictable cash flow, and strong 1031 exchange demand. Buyers assigned minimal spread between the two.
That calculus has changed materially. In 2026, CVS and Walgreens represent fundamentally different credit profiles, operational trajectories, and risk-adjusted return propositions. If you are underwriting a pharmacy NNN deal today without distinguishing between them, you are leaving significant analytical work on the table.
Here is how to think about the divergence and what it means for cap rate pricing, lease evaluation, and portfolio positioning.
The Credit Divergence: What the Financials Are Telling You
Walgreens: A Credit Story Under Stress
Walgreens Boots Alliance entered 2026 in a structurally weakened position. The company completed a take-private transaction with Sycamore Partners in mid-2025, which removed its publicly traded equity as a reference point but did not resolve its core operational challenges. The deal loaded significant debt onto an already leveraged balance sheet.
For NNN investors, the take-private creates a specific underwriting problem: reduced financial transparency. Public company credit tenants come with quarterly filings, bond ratings, and analyst coverage. A private Walgreens is harder to monitor on an ongoing basis, and the debt structure post-acquisition adds layers of complexity that standard NNN underwriting frameworks were not built to handle.
The operational picture compounds the credit concern. Walgreens has been closing hundreds of underperforming locations, renegotiating leases, and contracting its store footprint. When a tenant is actively shrinking, renewal probability at lease expiration deserves heightened scrutiny, particularly for locations in secondary markets or lower-traffic corridors.
CVS: Operational Challenges, But a More Legible Credit Profile
CVS is not without its own pressures. The company has faced margin compression in its pharmacy benefit management segment, integration challenges from its Aetna acquisition, and ongoing reimbursement rate headwinds from PBM reform discussions in Washington. CVS also announced store closures in recent years, though at a more controlled pace than Walgreens.
The critical distinction is that CVS remains a publicly traded, investment-grade credit with active bond market pricing. Its credit default swap spreads and bond yields give you real-time market signals on perceived credit risk. CVS carries an investment-grade rating, and while that rating has faced pressure, it provides a framework that Walgreens no longer offers in the same way.
CVS has also made more deliberate moves toward healthcare services integration, building out its MinuteClinic and HealthHUB formats. That operational pivot is relevant to NNN investors because it speaks to how CVS views its physical store footprint: as a healthcare delivery asset, not just a retail pharmacy. Tenants with strategic conviction around their real estate tend to honor leases differently than tenants in pure cost-cutting mode.
How to Underwrite Pharmacy NNN Deals in This Environment
Step 1: Separate the Lease from the Brand
Pharmacy NNN leases often carry absolute NNN structures with 20-25 year primary terms and options. That structure is attractive. But the value of a long lease term is only as good as the tenant's ability and willingness to perform through that term.
Start by identifying the actual lease obligor. Is it the parent entity, a subsidiary, or a guarantor structure? Post-Walgreens take-private, the guarantee stack matters more than it did when the obligor was a publicly traded company with transparent financials.
Step 2: Run Location-Level Viability Analysis
With both chains actively rationalizing their store networks, location quality has moved from a secondary consideration to a primary one. A Walgreens in a dense, high-traffic urban or suburban market with strong prescription volume is a fundamentally different asset than a Walgreens in a rural secondary market with a lease expiring in seven years.
Key location metrics to stress-test: population density within a 1-mile and 3-mile radius, proximity to major traffic generators (hospitals, medical office buildings, grocery anchors), co-tenancy in the immediate trade area, and whether the site has been identified in publicly available closure announcements.
Step 3: Price the Credit Spread Correctly
Cap rate spreads between CVS and Walgreens assets have widened in 2026. In prior cycles, a 10-25 basis point differential was common. Today, well-located Walgreens assets with shorter remaining lease terms are trading at materially wider spreads, reflecting both the credit uncertainty and the optionality discount investors demand when renewal is less certain.
For buyers, this creates a genuine valuation question: are you being compensated adequately for the incremental risk? A 50-75 basis point cap rate premium on a Walgreens deal over a comparable CVS asset may or may not be sufficient depending on lease term remaining, location quality, and your assessment of renewal probability.
Step 4: Stress-Test the Residual Real Estate
NNN investors often underweight residual value analysis because the long lease term pushes the question far into the future. In a pharmacy closure environment, that analysis deserves more weight today.
Pharmacy boxes typically run 10,000-15,000 square feet on well-located out-parcels or pad sites. The real estate itself is often redeployable: urgent care clinics, dialysis centers, dental service organizations, and medical retail users have been active acquirers of former pharmacy boxes. Understanding what the real estate is worth vacant, and who would lease or buy it, is essential underwriting when lease expiration or early termination is a realistic scenario.
What This Means for 1031 Exchange Buyers and Portfolio Investors
1031 exchange buyers are often under timing pressure, which creates risk in a market where credit differentiation matters this much. The instinct to close quickly on a familiar brand-name NNN tenant can override careful underwriting.
For portfolio investors building NNN exposure across multiple pharmacy assets, the concentration question is no longer academic. A portfolio heavy in Walgreens leases carries a correlated credit risk that needs to be reflected in underwriting assumptions and reserve planning.
For buyers seeking pure income stability with minimal management, CVS assets at current market pricing may offer a more defensible risk-adjusted profile, even at tighter cap rates. For buyers with higher risk tolerance and active asset management capability, select Walgreens deals in proven locations may offer yield pickup worth pursuing, provided the location analysis supports it.
The Kentwood Capital Perspective
Pharmacy NNN has been a cornerstone of the single-tenant net lease market for two decades. The sector is not broken, but it requires more rigorous, differentiated underwriting than it did five years ago.
At Kentwood Capital, we evaluate pharmacy NNN assets with equal attention to tenant credit, location fundamentals, and residual real estate value. Whether you are evaluating a CVS or Walgreens deal for a 1031 exchange or building a diversified NNN portfolio, the frameworks above are where the real underwriting work begins.
If you are looking at a pharmacy NNN deal and want a second set of analytical eyes, reach out to the Kentwood Capital team.